Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Novartis, while announcing its FDA approval for Mayzent in 2019, said that upto 80 per cent of patients with relapsing remitting MS will develop SPMS and the drug addresses a critical unmet need for ...

PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is ...

Genezen, a best-in-class gene therapy contract development and manufacturing organization (CDMO), is pleased to announce Dr. Pam Stetkiewicz and Stuart Auerbach have joined its Board of ...

Novartis is just months away from filing ... in phase 3 trials for chronic inducible urticaria (CINDU) and multiple sclerosis (MS), and in phase 2 for hidradenitis suppurativa (HS) and food ...

Seaport names Lauren White as CFO. Ms. White most recently served as CFO at ImmunoGen prior to its acquisition by AbbVie for ...

Additionally, Ms. White helped to maximize the successful commercial launch of ELAHERE ®, a first-in-class antibody-drug conjugate ... responsibility at Novartis (NYSE: NVS), most recently ...

Before Novartis, Ms. White held strategy and marketing roles with Boston ... including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being ...

The University of Queensland's capabilities in drug discovery and development are set to be strengthened ... cutting-edge ...